Client NewsOKYO Pharma Limited: Director/PDMR Shareholding
London and New York, NY, 18 May, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 25,000 ADSs (each representing 65 ordinary shares of no par value in the market) at a price of US$3.8749 per ADS.
The acquisition increase Mr Cerrone’s beneficial interests in the capital of the Company from 39.52% to 39.64% (however the impact of the announced offering closing on 19 May 2022 (the “Offering”) will reduce this holding to, in aggregate, 38.50% after allowing for; (i) the ordinary shares to be issued in the Offering; and (ii) the 25,000 ADS purchased by Mr Cerrone in the Offering).
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.